PharmAust Completes enrolment of second patient cohort in MND/ALS trial
PharmAust (PAA) completes the enrolment of the second cohort of patients in its phase...
PharmAust Reports ongoing positive outcomes for canine cancer treatment
PharmAust (PAA) claims a 12-year-old beagle in its clinical trial for the treatment of canine...
PharmAust Gets approval to increase dosage in MPL trial
PharmAust (PAA) has received the green light from the trial safety committee to increase the...
PharmAust Receives first $200k instalment for Phase 1 MND trial, appoints trial manager
Clinical-stage biotechnology company PharmAust (PAA) receives over $201,000 under the first...
PharmAust Successfully produces smaller GMP tablets
PharmAust’s (PAA) upcoming human trials receives a major boost as the company’s GMP monepantel (MPL) tablets has been...
PharmAust: Completes investigations on COVID-19 infection agent
PharmAust (PAA) has investigated the effects of monepantel (MPL) and monepantel sulfone (MPLS) on SARS-CoV2 infection, the...
PharmAust (PAA) has officially started recruiting patients for a second-phase clinical trial testing one of its key drugs against cancer in dogs
The...
